发明申请
US20140073650A1 PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS
有权
使用PI-1833模拟蛋白的抗氧化蛋白酶抑制剂
- 专利标题: PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS
- 专利标题(中): 使用PI-1833模拟蛋白的抗氧化蛋白酶抑制剂
-
申请号: US14035453申请日: 2013-09-24
-
公开(公告)号: US20140073650A1公开(公告)日: 2014-03-13
- 发明人: Harshani R. Lawrence , Said M. Sebti , Sevil Ozcan
- 申请人: H. Lee Moffitt Cancer Center and Research Institute, Inc
- 申请人地址: US FL Tampa
- 专利权人: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- 当前专利权人: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- 当前专利权人地址: US FL Tampa
- 主分类号: C07D413/04
- IPC分类号: C07D413/04 ; C07D271/06
摘要:
Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer).
公开/授权文献
信息查询